JP2007537295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007537295A5 JP2007537295A5 JP2007513432A JP2007513432A JP2007537295A5 JP 2007537295 A5 JP2007537295 A5 JP 2007537295A5 JP 2007513432 A JP2007513432 A JP 2007513432A JP 2007513432 A JP2007513432 A JP 2007513432A JP 2007537295 A5 JP2007537295 A5 JP 2007537295A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- compound
- aliphatic
- optionally substituted
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57130904P | 2004-05-14 | 2004-05-14 | |
| US60/571,309 | 2004-05-14 | ||
| PCT/US2005/016902 WO2005113541A1 (en) | 2004-05-14 | 2005-05-13 | Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007537295A JP2007537295A (ja) | 2007-12-20 |
| JP2007537295A5 true JP2007537295A5 (enExample) | 2008-06-26 |
| JP5132305B2 JP5132305B2 (ja) | 2013-01-30 |
Family
ID=35106760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513432A Expired - Lifetime JP5132305B2 (ja) | 2004-05-14 | 2005-05-13 | Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US7354939B2 (enExample) |
| EP (5) | EP3608315B1 (enExample) |
| JP (1) | JP5132305B2 (enExample) |
| CN (1) | CN1976919A (enExample) |
| AR (2) | AR051735A1 (enExample) |
| AU (1) | AU2005245885B2 (enExample) |
| BR (1) | BRPI0511111A (enExample) |
| CA (1) | CA2566461C (enExample) |
| CY (1) | CY1122336T1 (enExample) |
| DK (1) | DK3305776T3 (enExample) |
| ES (4) | ES2651439T3 (enExample) |
| HU (1) | HUE047130T2 (enExample) |
| IL (1) | IL179207A0 (enExample) |
| LT (1) | LT3305776T (enExample) |
| MX (1) | MXPA06013209A (enExample) |
| NO (1) | NO20065727L (enExample) |
| NZ (1) | NZ551582A (enExample) |
| PL (1) | PL3305776T3 (enExample) |
| PT (1) | PT3305776T (enExample) |
| RU (1) | RU2376299C2 (enExample) |
| SI (1) | SI3305776T1 (enExample) |
| TW (1) | TW200607803A (enExample) |
| UA (1) | UA84930C2 (enExample) |
| WO (1) | WO2005113541A1 (enExample) |
| ZA (1) | ZA200609975B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004083203A1 (en) * | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| US7462612B2 (en) * | 2004-03-26 | 2008-12-09 | Vertex Pharmaceuticals Incorporated | Pyridine inhibitors of ERK2 and uses thereof |
| JP5132305B2 (ja) * | 2004-05-14 | 2013-01-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体 |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| DE602007009932D1 (de) * | 2006-02-16 | 2010-12-02 | Schering Corp | Pyrrolidin-derivate als erk-hemmer |
| BRPI0812450A2 (pt) * | 2007-06-05 | 2019-09-24 | Schering Corp | derivados de indazol policíclicos e seu uso como inibidores de erk para o tratamento de câncer |
| JP5276676B2 (ja) | 2008-02-21 | 2013-08-28 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｅｒｋ阻害剤である化合物 |
| CN102146074B (zh) * | 2011-01-26 | 2013-02-06 | 江苏先声药物研究有限公司 | 吡咯衍生物的制备方法及应用 |
| WO2012172093A1 (en) | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dihydroindolizine derivate as metabotropic glutamate receptor modulators |
| CA2926645C (en) | 2013-10-14 | 2022-10-25 | Indiana University Research And Technology Corporation | Use of acamprosate to modulate erk 1/2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd |
| EP3061754A4 (en) | 2013-10-23 | 2017-03-22 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3082957B1 (en) * | 2013-12-20 | 2022-04-06 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |
| JP6678583B2 (ja) * | 2013-12-20 | 2020-04-22 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | ２型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを用いるがん処置 |
| WO2015095842A2 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| WO2015095807A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of egfr and erk inhibitors |
| WO2015095831A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mtor and erk inhibitors |
| WO2015095835A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers |
| MX394252B (es) * | 2013-12-20 | 2025-03-21 | Biomed Valley Discoveries Inc | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf |
| US11013743B2 (en) * | 2013-12-20 | 2021-05-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of CDK and ERK inhibitors |
| WO2015095833A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
| WO2015095838A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mek type i and erk inhibitors |
| ES3009552T3 (en) * | 2015-01-30 | 2025-03-27 | Biomed Valley Discoveries Inc | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt |
| CA2975116C (en) * | 2015-01-30 | 2022-10-11 | Biomed Valley Discoveries, Inc. | Crystalline c21h22c12n4o2 malonate |
| WO2016187028A1 (en) * | 2015-05-15 | 2016-11-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds, synthesis thereof, and intermediates thereto |
| CN107849046B (zh) * | 2015-06-03 | 2020-06-12 | 常州捷凯医药科技有限公司 | 作为erk抑制剂的杂环化合物 |
| EP3303335B1 (en) * | 2015-06-03 | 2021-07-28 | JS Innopharm (Shanghai) Ltd. | Heterocyclic compounds for treating psoriasis |
| PL3365334T3 (pl) | 2015-10-21 | 2024-11-25 | Otsuka Pharmaceutical Co., Ltd. | Związki benzolaktamu jako inhibitory kinazy białkowej |
| EP3170822A1 (en) | 2015-11-18 | 2017-05-24 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
| CA3037064A1 (en) * | 2016-10-05 | 2018-04-12 | Zeno Royalties & Milestones, LLC | Spirocyclic compounds |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| EP3694518A1 (en) * | 2017-10-12 | 2020-08-19 | Novartis AG | Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers |
| WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
| WO2020223177A1 (en) * | 2019-04-29 | 2020-11-05 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
| WO2021020841A1 (en) * | 2019-07-29 | 2021-02-04 | Standigm Inc. | Composition for preventing or treating metabolic liver disease |
| EP4212531A1 (en) | 2022-01-14 | 2023-07-19 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
| WO2023169480A1 (zh) * | 2022-03-08 | 2023-09-14 | 甘李药业股份有限公司 | 氘代化合物，及其制备方法和应用 |
| TW202400572A (zh) * | 2022-03-24 | 2024-01-01 | 美商生物醫學谷探索公司 | Erk的吡咯抑制劑之氘化類似物、其合成及其中間物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5565413A (en) * | 1994-12-06 | 1996-10-15 | Zeneca Limited | Substituted pyridyl phenyl ketone herbicides |
| US5472966A (en) * | 1995-03-29 | 1995-12-05 | Bristol-Myers Squibb Company | Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE60003550T2 (de) * | 1999-05-14 | 2004-04-15 | Ortho-Mcneil Pharmaceutical, Inc. | Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung |
| WO2000078747A1 (en) * | 1999-06-22 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Acylhydrazine derivatives, process for preparing the same and use thereof |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| WO2003091246A1 (en) * | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| JP4570955B2 (ja) * | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
| EP2256108B1 (en) * | 2002-07-18 | 2016-03-23 | Janssen Pharmaceutica NV | Substituted triazine kinase inhibitors |
| GB0217780D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| US7304071B2 (en) * | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| WO2004083203A1 (en) * | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| JP5132305B2 (ja) * | 2004-05-14 | 2013-01-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体 |
-
2005
- 2005-05-13 JP JP2007513432A patent/JP5132305B2/ja not_active Expired - Lifetime
- 2005-05-13 EP EP19199330.2A patent/EP3608315B1/en not_active Expired - Lifetime
- 2005-05-13 EP EP17184079.6A patent/EP3305776B1/en not_active Expired - Lifetime
- 2005-05-13 ES ES14163944.3T patent/ES2651439T3/es not_active Expired - Lifetime
- 2005-05-13 CA CA2566461A patent/CA2566461C/en not_active Expired - Lifetime
- 2005-05-13 NZ NZ551582A patent/NZ551582A/en not_active IP Right Cessation
- 2005-05-13 ES ES19199330T patent/ES2897422T3/es not_active Expired - Lifetime
- 2005-05-13 RU RU2006144445/04A patent/RU2376299C2/ru active
- 2005-05-13 PL PL17184079T patent/PL3305776T3/pl unknown
- 2005-05-13 MX MXPA06013209A patent/MXPA06013209A/es active IP Right Grant
- 2005-05-13 TW TW094115644A patent/TW200607803A/zh unknown
- 2005-05-13 US US11/128,870 patent/US7354939B2/en not_active Ceased
- 2005-05-13 ES ES17184079T patent/ES2751761T3/es not_active Expired - Lifetime
- 2005-05-13 AR ARP050101987A patent/AR051735A1/es not_active Application Discontinuation
- 2005-05-13 WO PCT/US2005/016902 patent/WO2005113541A1/en not_active Ceased
- 2005-05-13 PT PT171840796T patent/PT3305776T/pt unknown
- 2005-05-13 DK DK17184079T patent/DK3305776T3/da active
- 2005-05-13 EP EP21190432.1A patent/EP3943489A1/en active Pending
- 2005-05-13 ZA ZA200609975A patent/ZA200609975B/en unknown
- 2005-05-13 EP EP05748073.3A patent/EP1753738B1/en not_active Expired - Lifetime
- 2005-05-13 EP EP14163944.3A patent/EP2799434B1/en not_active Expired - Lifetime
- 2005-05-13 UA UAA200613208A patent/UA84930C2/ru unknown
- 2005-05-13 ES ES05748073.3T patent/ES2513965T3/es not_active Expired - Lifetime
- 2005-05-13 SI SI200532267T patent/SI3305776T1/sl unknown
- 2005-05-13 LT LTEP17184079.6T patent/LT3305776T/lt unknown
- 2005-05-13 CN CNA200580021418XA patent/CN1976919A/zh active Pending
- 2005-05-13 AU AU2005245885A patent/AU2005245885B2/en not_active Expired
- 2005-05-13 HU HUE17184079A patent/HUE047130T2/hu unknown
- 2005-05-13 BR BRPI0511111-0A patent/BRPI0511111A/pt not_active IP Right Cessation
-
2006
- 2006-11-13 IL IL179207A patent/IL179207A0/en unknown
- 2006-12-12 NO NO20065727A patent/NO20065727L/no not_active Application Discontinuation
-
2013
- 2013-08-23 US US14/544,396 patent/USRE46097E1/en not_active Expired - Lifetime
-
2016
- 2016-06-28 US US15/195,021 patent/USRE47318E1/en not_active Expired - Lifetime
- 2016-11-18 AR ARP160103545A patent/AR106755A2/es active IP Right Grant
-
2019
- 2019-03-25 US US16/363,905 patent/USRE48266E1/en not_active Expired - Lifetime
- 2019-12-03 CY CY20191101265T patent/CY1122336T1/el unknown
-
2020
- 2020-10-15 US US17/071,566 patent/USRE49500E1/en not_active Expired - Lifetime
-
2023
- 2023-02-22 US US18/173,004 patent/US20230183276A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007537295A5 (enExample) | ||
| JP2007516714A5 (ja) | 間葉系前駆細胞の骨芽細胞への分化を誘導する化合物の同定方法 | |
| JP2007521309A5 (enExample) | ||
| JP2010539101A5 (enExample) | ||
| RU2002107203A (ru) | Производные N-гетероциклических соединений в качестве ингибиторов синтазы оксида азота (nos) | |
| JP2008504265A5 (enExample) | ||
| JP2005502658A5 (enExample) | ||
| JP2007514047A5 (enExample) | ||
| JP2002529532A5 (enExample) | ||
| JP2009524691A5 (enExample) | ||
| JP2002536300A5 (enExample) | ||
| JP2001514282A5 (enExample) | ||
| CN1246119A (zh) | 吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途 | |
| JP2007511047A5 (enExample) | ||
| JP2004502755A5 (enExample) | ||
| JP2007506721A5 (enExample) | ||
| JP2007515467A5 (enExample) | ||
| JP2010517991A5 (enExample) | ||
| JP2003514821A5 (enExample) | ||
| JP2008526897A5 (enExample) | ||
| JP2006526587A5 (enExample) | ||
| JPWO2019141774A5 (enExample) | ||
| CN106459108B (zh) | 包含磷酰胆碱衍生物的分离材料 | |
| JP2005526149A5 (enExample) | ||
| JP2005526073A5 (enExample) |